一种有前途的新型HBV血清标志物——HBcrAg  

Hepatitis B virus core-related antigen:A promising new serum marker for hepatitis B virus

作　　者：陈恩强[1] 唐红[1] CHEN Enqiang;TANG Hong(Center of Infectious Diseases,West China Hospital of Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院感染性疾病中心

出　　处：《临床肝胆病杂志》2019年第10期2159-2162,共4页Journal of Clinical Hepatology

摘　　要：乙型肝炎核心相关抗原(HBcrAg)是HBV新的血清标志物,由HBV前C/C区基因编码的几种抗原共同组成,包括HBcAg、HBeAg和P22cr前体蛋白。HBcrAg与HBsAg定量检测结果的相关性一般,彼此不能互相取代。血清中HBcrAg水平可反映慢性乙型肝炎患者肝细胞内cccDNA的含量及转录活性,也可能反映整合HBVDNA的转录活性。此外,HBcrAg可用于评价核苷(酸)类似物和PEG-IFN的抗病毒效果,预测核苷(酸)类似物治疗患者停药后的复发风险、肝细胞癌的发展和术后复发风险。据此,目前认为HBcrAg是一种非常有前途的新型HBV血清标志物。Hepatitis B virus core-related antigen (HBcrAg) is a new serum biomarker for hepatitis B virus (HBV) and is composed of several antigens encoded by the pre-C/C region gene of HBV,including HBcAg,HBeAg,and P22cr precursor protein.There is a poor correlation between HBcrAg and HBsAg and they cannot replace each other.Serum HBcrAg level can reflect the content and transcriptional activity of cccDNA in hepatocytes of patients with chronic hepatitis B,as well as the transcriptional activity of integrated HBV DNA.In addition,HBcrAg can be used to evaluate the antiviral effect of nucleos(t)ide analogues and pegylated interferon- and predict recurrence risk after withdrawal of nucleos(t)ide analogues and the development risk and recurrence of hepatocellular carcinoma after surgery.Therefore,serum HBcrAg is a promising new serum marker for HBV.

关 键 词：乙型肝炎病毒 乙型肝炎核心抗原 乙型肝炎核心相关抗原 DNA 环状 

分 类 号：R512.62[医药卫生—内科学]